Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial.

@article{Hoover1993AdjuvantAS,
  title={Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial.},
  author={Herbert C. Hoover and J S Brandhorst and Larry Peters and M G Surdyke and Yasuo Takeshita and Juan Andr{\'e}s Madariaga and Larry R. Muenz and Melisha G Hanna},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1993},
  volume={11 3},
  pages={390-9}
}
PURPOSE Patients with colon or rectal cancer were entered onto a prospectively randomized, controlled clinical trial of active specific immunotherapy (ASI) with an autologous tumor cell-bacillus Calmette-Guérin (BCG) vaccine. We investigated whether ASI could improve disease-free status and survival. PATIENTS AND METHODS Ninety-eight patients with Dukes' stage B2-C3 colon or rectal cancer were randomized into groups treated by resection alone or resection plus ASI. Eighty patients met all… CONTINUE READING
63 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

Similar Papers

Loading similar papers…